Status:
COMPLETED
Phase I/II Study of TSU-68 for Advanced Hepatocellular Carcinoma
Lead Sponsor:
Taiho Pharmaceutical Co., Ltd.
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
20-74 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of Orantinib, an oral tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2, platelet-derived growth factor recept...
Detailed Description
As HCC is a highly vascular tumor, a number of antiangiogenic agents have been tested for the treatment of HCC. Orantinib is an orally administered, small-molecule, multiple receptor tyrosine kinase i...
Eligibility Criteria
Inclusion
- Age 20-74
- PS 0-2
- Patients who did not respond to surgery, RFA, TAE, chemotherapy, or radiotherapy
- Chid-Pugh A or B
- At least one measurable lesion by RECIST criteria
Exclusion
- Large amount of pleural effusion or ascites
- Esophageal varices
- Simultaneously active double cancer
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2012
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00784290
Start Date
September 1 2003
End Date
March 1 2012
Last Update
March 26 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chiba University Hospital
Inohana Chuo-ku Chiba, Chiba, Japan, 260-8670